Bacteria as gene therapy vectors for cancer

Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Fourth Edition

Volumn , Issue , 2015, Pages 259-269

  Byrne, William L ^a   Tangney, Mark ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85042505176     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b18002     Document Type: Chapter

References (123)

1. Abelmann, H. W.1951. Cancer as I See It.New York: New York Philosophical Library.
2. Aggarwal, A., S.Kumar, R.Jaffe, D.Hone, M.Gross, and J.Sadoff. 1990. Oral Salmonella: Malaria circumsporozoite recombinants induce specific CD8+ cytotoxic T cells. J Exp Med172(4):1083-1090.
3. Ahmad, S., G.Casey, M.Cronin, S.Rajendran, P.Sweeney, M.Tangney, and G. C.O’Sullivan. 2011. Induction of effective antitumor response after mucosal bacterial vector mediated DNA vaccination with endogenous prostate cancer specific antigen. J Urol186(2):687-693.
4. Ahmad, S., P.Sweeney, G. C.Sullivan, and M.Tangney. 2012. DNA vaccination for prostate cancer, from preclinical to clinical trials—Where we stand?Genet Vaccines Ther10(1):9.
5. Baban, C. K., M. Cronin, A. R. Akin, A. O’Brien, X. Gao, S. Tabirca, K. P.Francis, and M.Tangney. 2012. Bioluminescent bacterial imaging in vivo. J Vis Exp2012(69):e4318.
6. Baban, C. K., M.Cronin, D.O’Hanlon, G. C.O’Sullivan, and M.Tangney. 2010. Bacteria as vectors for gene therapy of cancer. Bioeng Bugs1(6):385-394.
7. Bermudes, D., B.Low, and J. M.Pawelek. 2000. Tumor-targeted salmonella: Strain development and expression of the HSV-tK effector gene. Methods Mol Med35:419-436.
8. Bettegowda, C., L. H. Dang, R. Abrams, D. L. Huso, L. Dillehay, I.Cheong, N.Agrawalet al.2003. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Natl Acad Sci USA100(25):15083-15088.
9. Blache, C. A., E. R. Manuel, T. I. Kaltcheva, A. N. Wong, J. D. Ellenhorn, B. R. Blazar, and D. J. Diamond. 2012. Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth. Cancer Res 72(24):6447-6456.
10. Brockstedt, D. G., M. A.Giedlin, M. L.Leong, K. S.Bahjat, Y.Gao, W.Luckett, W.Liu, D. N.Cook, D. A.Portnoy, and T. W.Dubensky, Jr. 2004. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci USA101(38):13832-13837.
11. Buttaro, C. and J. H.Fruehauf. 2010. Engineered E. coli as vehicles for targeted therapeutics. Curr Gene Ther10:27-33.
12. Byrne, W. L., A.Delille, C.Kuo, J. S.de Jong, G. M.van Dam, K. P.Francis, and M.Tangney. 2013. Use of optical imaging to progress novel therapeutics to the clinic. J Control Release172(2):523-534.
13. Byrne, W. L., K. H.Mills, J. A.Lederer, and G. C.O’Sullivan. 2011. Targeting regulatory T cells in cancer. Cancer Res71(22):6915-6920.
14. Chen, G., D. P.Wei, L. J.Jia, B.Tang, L.Shu, K.Zhang, Y.Xuet al.2009. Oral delivery of tumor-targeting Salmonella exhibits promising therapeutic efficacy and low toxicity. Cancer Sci100(12):2437-2443.
15. Chorobik, P., D.Czaplicki, K.Ossysek, and J.Bereta. 2013. Salmonella and cancer: From pathogens to therapeutics. Acta Biochim Pol60(3):285-297.
16. Chou, C. K., J. Y.Hung, J. C.Liu, C. T.Chen, and M. C.Hung. 2006. An attenuated Salmonella oral DNA vaccine prevents the growth of hepatocellular carcinoma and colon cancer that express alpha-fetoprotein. Cancer Gene Ther13(8):746-752.
17. Collins, S. A., B. A.Guinn, P. T.Harrison, M. F.Scallan, G. C.O’Sullivan, and M.Tangney. 2008. Viral vectors in cancer immunotherapy: Which vector for which strategy?Curr Gene Ther8(2):66-78.
18. Collins, S. A., K.Hiraoka, A.Inagaki, N.Kasahara, and M.Tangney. 2012. PET imaging for gene & cell therapy. Curr Gene Ther12(1):20-32.
19. Courvalin, P., S.Goussard, and C.Grillot-Courvalin. 1995. Gene transfer from bacteria to mammalian cells. C R Acad Sci III318(12):1207-1212.
20. Critchley-Thorne, R. J., A. J.Stagg, and G.Vassaux. 2006. Recombinant Escherichia coli expressing invasin targets the Peyer’s patches: The basis for a bacterial formulation for oral vaccination. Mol Ther14(2):183-191.
21. Cronin, M., A. R.Akin, S. A.Collins, J.Meganck, J. B.Kim, C. K.Baban, S. A.Joyceet al.2012a. High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting. PLoS One7(1):e30940.
22. Cronin, M., D.Morrissey, S.Rajendran, S. M.El Mashad, D.van Sinderen, G. C.O’Sullivan, and M.Tangney. 2010. Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors. Mol Ther18(7):1397-1407.
23. Cronin, M., R. M.Stanton, K. P.Francis, and M.Tangney. 2012b. Bacterial vectors for imaging and cancer gene therapy: A review. Cancer Gene Ther19:731-740.
24. Cummins, J. and M.Tangney. 2013. Bacteria and tumours: Causative agents or opportunistic inhabitants?Infect Agent Cancer8(1):11.
25. Cunningham, C. and J.Nemunaitis. 2001. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. Hum Gene Ther12(12):1594-1596.
26. Dang, L. H., C. Bettegowda, D. L. Huso, K. W. Kinzler, andB.Vogelstein. 2001. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA98(26):15155-15160.
27. Dietrich, G., A. Bubert, I. Gentschev, Z. Sokolovic, A. Simm, A.Catic, S. H.Kaufmann, J.Hess, A. A.Szalay, and W.Goebel. 1998. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nat Biotechnol16(2):181-185.
28. Dietzel, F.1983. Basic principles in hyperthermic tumor therapy. Recent Results Cancer Res86:177-190.
29. Dietzel, F. and D.Gericke. 1977. Intensification of the oncolysis by clostridia by means of radio-frequency hyperthermy in experiments on animals—Dependence on dosage and on intervals (author’s transl). Strahlentherapie153(4):263-266.
30. Dietzel, F., D.Gericke, and W.Konig. 1976. Tumor hyperthermia using high frequency for increase of oncolysis by clostridium butyricum (M 55). Strahlentherapie152(6):537-541.
31. Donnelly, J. J., J. B.Ulmer, J. W.Shiver, and M. A.Liu. 1997. DNA vaccines. Annu Rev Immunol15:617-648.
32. Dougan, G., S. Chatfield, M. Roberts, I. Charles, S. Comerford, L. J.Li, and N.Fairweather. 1990. Bacterial pathogens—A route to oral drug delivery. Biochem Soc Trans18(5):746-748.
33. Edelson, B. T. and E. R.Unanue. 2002. MyD88-dependent but Tolllike receptor 2-independent innate immunity to Listeria: No role for either in macrophage listericidal activity. J Immunol169(7):3869-3875.
34. Engelbart, K. and D.Gericke. 1964. Oncolysis by Clostridia. V. Transplanted Tumors of the Hamster. Cancer Res24:239-242.
35. Fairweather, N. F., S. N. Chatfield, I. G. Charles, M. Roberts, M.Lipscombe, L. J.Li, D.Strugnell, S.Comerford, J.Tite, and G.Dougan. 1990. Use of live attenuated bacteria to stimulate immunity. Res Microbiol141(7-8):769-773.
36. Fest, S., N.Huebener, M.Bleeke, T.Durmus, A.Stermann, A.Woehler, B.Baykanet al.2009. Survivin minigene DNA vaccination is effective against neuroblastoma. Int J Cancer125(1):104-114.
37. Fest, S., N. Huebener, S. Weixler, M. Bleeke, Y. Zeng, A. Strandsby, R.Volkmer-Engertet al.2006. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. Cancer Res66(21):10567-10575.
38. Folkman, J.1990. What is the evidence that tumors are angiogenesis dependent?J Natl Cancer Inst82(1):4-6.
39. Fox, M. E., M. J.Lemmon, M. L.Mauchline, T. O.Davis, A. J.Giaccia, N. P.Minton, and J. M.Brown. 1996. Anaerobic bacteria as a delivery system for cancer gene therapy: In vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther3(2):173-178.
40. Freeman, S. M.2000. Suicide gene therapy. Adv Exp Med Biol465:411-422.
41. Fu, G. F., X.Li, Y. Y.Hou, Y. R.Fan, W. H.Liu, and G. X.Xu. 2005. Bifidobacterium longum as an oral delivery system of endostatin for gene therapy on solid liver cancer. Cancer Gene Ther12(2):133-140.
42. Ganai, S., R. B.Arenas, and N. S.Forbes. 2009. Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. Br J Cancer101(10):1683-1691.
43. Gericke, D. and K.Engelbart. 1964. Oncolysis by Clostridia. Ii. Experiments on a tumor spectrum with a variety of clostridia in combination with heavy metal. Cancer Res24:217-221.
44. Guan, G. F., M.Zhao, L. M.Liu, C. S.Jin, K.Sun, D. J.Zhang, D. J.Yu, H. W.Cao, Y. Q.Lu, and L. J.Wen. 2013. Salmonella typhimurium mediated delivery of Apoptin in human laryngeal cancer. Int J Med Sci10(12):1639-1648.
45. Guimaraes, V. D., J. E.Gabriel, F.Lefevre, D.Cabanes, A.Gruss, P.Cossart, V.Azevedo, and P.Langella. 2005. Internalinexpressing Lactococcus lactis is able to invade small intestine of guinea pigs and deliver DNA into mammalian epithelial cells. Microbes Infect7(5-6):836-844.
46. Hanahan, D. and R. A.Weinberg. 2011. Hallmarks of cancer: The next generation. Cell144(5):646-674.
47. Heppner, F. and J. R.Mose. 1978. The liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium. Acta Neurochir (Wien)42(1-2):123-125.
48. Hiroshima, Y., M.Zhao, Y.Zhang, A.Maawy, M. K.Hassanein, F.Uehara, S.Miwaet al.2013. Comparison of efficacy of Salmonella typhimurium A1-R and chemotherapy on stem-like and non-stem human pancreatic cancer cells. Cell Cycle12(17):2774-2780.
49. Hormaeche, C. E.1991. Live attenuated Salmonella vaccines and their potential as oral combined vaccines carrying heterologous antigens. J Immunol Methods142(1):113-120.
50. Hu, B., L.Kou, C.Li, L. P.Zhu, Y. R.Fan, Z. W.Wu, J. J.Wang, and G. X.Xu. 2009. Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth. Cancer Gene Ther16(8):655-663.
51. Huebener, N., S.Fest, A.Strandsby, E.Michalsky, R.Preissner, Y.Zeng, G.Gaedicke, and H. N.Lode. 2008. A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity. Mol Cancer Ther7(7):2241-2251.
52. Jia, L. J., D. P.Wei, Q. M.Sun, Y.Huang, Q.Wu, and Z. C.Hua. 2007. Oral delivery of tumor-targeting Salmonella for cancer therapy in murine tumor models. Cancer Sci98(7):1107-1112.
53. Jia, L. J., H. M.Xu, D. Y.Ma, Q. G.Hu, X. F.Huang, W. H.Jiang, S. F.Li, K. Z.Jia, Q. L.Huang, and Z. C.Hua. 2005. Enhanced therapeutic effect by combination of tumor-targeting Salmonella and endostatin in murine melanoma model. Cancer Biol Ther4(8):840-845.
54. Jiang, S. N., S. H.Park, H. J.Lee, J. H.Zheng, H. S.Kim, H. S.Bom, Y.Honget al.2013. Engineering of bacteria for the visualization of targeted delivery of a cytolytic anticancer agent. Mol Ther21(11):1985-1995.
55. Kim, S. H., F. Castro, D. Gonzalez, P. C. Maciag, Y. Paterson, and C.Gravekamp. 2008. Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases. Br J Cancer99(5):741-749.
56. Kimura, N. T., S.Taniguchi, K.Aoki, and T.Baba. 1980. Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res40(6):2061-2068.
57. King, I., M.Itterson, and D.Bermudes. 2009. Tumor-targeted Salmonella typhimurium overexpressing cytosine deaminase: A novel, tumor-selective therapy. Methods Mol Biol542:649-659.
58. Krick, E. L., K. U. Sorenmo, S. C. Rankin, I. Cheong, B. Kobrin, K. Thornton, K. W. Kinzler, B. Vogelstein, S. Zhou, and L. A.Diaz, Jr. 2012. Evaluation of Clostridium novyi-NT spores in dogs with naturally occurring tumors. Am J Vet Res73(1):112-118.
59. Lai, W. C. and M.Bennett. 1998. DNA vaccines. Crit Rev Immunol18(5):449-484.
60. Le, D. T., D. G.Brockstedt, R.Nir-Paz, J.Hampl, S.Mathur, J.Nemunaitis, D. H.Stermanet al.2012. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase I studies of safety and immune induction. Clin Cancer Res18(3):858-868.
61. Lee, C. H., C. L. Wu, and A. L. Shiau. 2005. Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model. Cancer Gene Ther12(2):175-184.
62. Lee, P.2010. Biocontainment strategies for live lactic acid bacteria vaccine vectors. Bioeng Bugs1(1):75-77.
63. Lehouritis, P., C.Springer, and M.Tangney. 2013. Bacterial-directed enzyme prodrug therapy. J Control Release170:120-131.
64. Leschner, S., K. Westphal, N. Dietrich, N. Viegas, J. Jablonska, M.Lyszkiewicz, S.Lienenklauset al.2009. Tumor invasion of Salmonella enterica serovar Typhimurium is accompanied by strong hemorrhage promoted by TNF-alpha. PLoS One4(8):e6692.
65. Li, X., G. F.Fu, Y. R.Fan, W. H.Liu, X. J.Liu, J. J.Wang, and G. X.Xu. 2003. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: Selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther10(2):105-111.
66. Liu, G., C. Bettegowda, Y. Qiao, V. Staedtke, K. W. Y. Chan, R. Bai, Y. Li, G. J. Riggins, K. W. Kinzler, and J. W. M. Bulte. 2013. Noninvasive imaging of infection after treatment with tumorhoming bacteria using chemical exchange saturation transfer (CEST) MRI. Magn Reson Med 70(6):1690-1698.
67. Liu, S. C., N. P.Minton, A. J.Giaccia, and J. M.Brown. 2002. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther9(4):291-296.
68. Loeffler, M., G.Le’Negrate, M.Krajewska, and J. C.Reed. 2007. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci USA104(31):12879-12883.
69. Loeffler, M., G.Le’Negrate, M.Krajewska, and J. C.Reed. 2008. IL-18-producing Salmonella inhibit tumor growth. Cancer Gene Ther15(12):787-794.
70. Loeffler, M., G.Le’Negrate, M.Krajewska, and J. C.Reed. 2008. Inhibition of tumor growth using salmonella expressing Fas ligand. J Natl Cancer Inst100(15):1113-1116.
71. Loeffler, M., G.Le’Negrate, M.Krajewska, and J. C.Reed. 2009. Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth. Cancer Immunol Immunother58(5):769-775.
72. Loessner, H., A.Endmann, S.Leschner, H.Bauer, A.Zelmer, S.zur Lage, K.Westphal, and S.Weiss. 2008. Improving live attenuated bacterial carriers for vaccination and therapy. Int J Med Microbiol298(1-2):21-26.
73. Maciag, P. C., S.Radulovic, and J.Rothman. 2009. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine27(30):3975-3983.
74. Moese, J. R. and G.Moese. 1964. Oncolysis by Clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic Clostridia against the Ehrlich Carcinoma. Cancer Res24:212-216.
75. Morales, A., D.Eidinger, and A. W.Bruce. 1976. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol116(2):180-183.
76. Moreno, M., M. G.Kramer, L.Yim, and J. A.Chabalgoity. 2010. Salmonella as live trojan horse for vaccine development and cancer gene therapy. Curr Gene Ther10(1):56-76.
77. Morrissey, D., G. C.O’Sullivan, and M.Tangney. 2010. Tumour targeting with systemically administered bacteria. Curr Gene Ther10(1):3-14.
78. Nakamura, T., T.Sasaki, M.Fujimori, K.Yazawa, Y.Kano, J.Amano, and S.Taniguchi. 2002. Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors. Biosci Biotechnol Biochem66(11):2362-2366.
79. Nauts, H. C. and J. R.McLaren. 1990. Coley toxins—The first century. Adv Exp Med Biol267:483-500.
80. Nemunaitis, J., C. Cunningham, N. Senzer, J. Kuhn, J. Cramm, C. Litz, R. Cavagnolo, A. Cahill, C. Clairmont, and M. Sznol. 2003. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 10(10):737-744.
81. Niethammer, A. G., R.Xiang, J. C.Becker, H.Wodrich, U.Pertl, G.Karsten, B. P.Eliceiri, and R. A.Reisfeld. 2002. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth.Nat Med8(12):1369-1375.
82. O’Reilly, M. S., T.Boehm, Y.Shing, N.Fukai, G.Vasios, W. S.Lane, E.Flynn, J. R.Birkhead, B. R.Olsen, and J.Folkman. 1997. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell88(2):277-285.
83. O’Riordan, M., C. H.Yi, R.Gonzales, K. D.Lee, and D. A.Portnoy. 2002. Innate recognition of bacteria by a macrophage cytosolic surveillance pathway. Proc Natl Acad Sci USA99(21):13861-13866.
84. Ostertag, D., K. K.Amundson, F.Lopez Espinoza, B.Martin, T.Buckley, A. P.Galvao da Silva, A. H.Linet al.2012. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro Oncol14(2):145-159.
85. Ozoren, N., J.Masumoto, L.Franchi, T. D.Kanneganti, M.Body-Malapel, I.Erturk, R.Jagirdaret al.2006. Distinct roles of TLR2 and the adaptor ASC in IL-1beta/IL-18 secretion in response toListeria monocytogenes. J Immunol176(7):4337-4342.
86. Paglia, P., E.Medina, I.Arioli, C. A.Guzman, and M. P.Colombo. 1998. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood92(9):3172-3176.
87. Pawelek, J. M., K. B.Low, and D.Bermudes. 1997. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res57(20):4537-4544.
88. Pilgrim, S., J.Stritzker, C.Schoen, A.Kolb-Maurer, G.Geginat, M. J.Loessner, I.Gentschev, and W.Goebel. 2003. Bactofection of mammalian cells by Listeria monocytogenes: Improvement and mechanism of DNA delivery. Gene Ther10(24):2036-2045.
89. Prosser, G. A., J. N.Copp, A. M.Mowday, C. P.Guise, S. P.Syddall, E. M.Williams, C. N.Horvatet al.2013. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A. Biochem Pharmacol85(8):1091-1103.
90. Riedel, C. U., I. R.Monk, P. G.Casey, D.Morrissey, G. C.O’Sullivan, M.Tangney, C.Hill, and C. G.Gahan. 2007. Improved luciferase tagging system for Listeria monocytogenes allows real-time monitoring in vivo and in vitro. Appl Environ Microbiol73(9):3091-3094.
91. Scully, S. P.2000. Gene therapy: Clinical considerations. Clin Orthop Relat Res (379 Suppl):S55-S58.
92. Seavey, M. M., Z. K. Pan, P. C. Maciag, A. Wallecha, S. Rivera, Y. Paterson, and V. Shahabi. 2009. A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. Clin Cancer Res 15(3):924-932.
93. Shahabi, V., M.Reyes-Reyes, A.Wallecha, S.Rivera, Y.Paterson, and P.Maciag. 2008. Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol Immunother57(9):1301-1313.
94. Singh, R., M. E.Dominiecki, E. M.Jaffee, and Y.Paterson. 2005. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J Immunol175(6):3663-3673.
95. Sizemore, D. R., A. A.Branstrom, and J. C.Sadoff. 1995. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science270(5234):299-302.
96. Stritzker, J., P. J.Hill, I.Gentschev, and A. A.Szalay. 2010. Myristoylation negative msbB-mutants of probiotic E. coli Nissle 1917 retain tumor specific colonization properties but show less side effects in immunocompetent mice. Bioeng Bugs1(2):139-145.
97. Stritzker, J., S.Weibel, P. J.Hill, T. A.Oelschlaeger, W.Goebel, and A. A.Szalay. 2007. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol297(3):151-162.
98. Sylvester, R. J.2011. Bacillus Calmette-Guerin treatment of nonmuscle invasive bladder cancer. Int J Urol18(2):113-120.
99. Tangney, M.2010. Gene therapy for cancer: Dairy bacteria as delivery vectors. Discov Med10(52):195-200.
100. Tangney, M., S.Ahmad, S. A.Collins, and G. C.O’Sullivan. 2010. Gene therapy for prostate cancer. Postgrad Med122(3):166-180.
101. Tangney, M., G.Casey, J. O.Larkin, C. G.Collins, D.Soden, J.Cashman, M. C.Whelan, and G. C.O’Sullivan. 2006. Non-viral in vivo immune gene therapy of cancer: Combined strategies for treatment of systemic disease. Cancer Immunol Immunother55(11):1443-1450.
102. Tangney, M. and K. P. Francis. 2012. In vivo optical imaging in gene & cell therapy. Curr Gene Ther 12(1):2-11.
103. Tangney, M. and C. G.Gahan. 2010. Listeria monocytogenes as a vector for anti-cancer therapies. Curr Gene Ther10(1):46-55.
104. Tangney, M., J. P. van Pijkeren, and C. G. Gahan. 2010. The use of Listeria monocytogenes as a DNA delivery vector for cancer gene therapy. Bioeng Bugs 1(4):284-287.
105. Theys, J., A. W.Landuyt, S.Nuyts, L.Van Mellaert, P.Lambin, and J.Anne. 2001. Clostridium as a tumor-specific delivery system of therapeutic proteins. Cancer Detect Prev25(6):548-557.
106. Theys, J., O.Pennington, L.Dubois, G.Anlezark, T.Vaughan, A.Mengesha, W.Landuytet al.2006. Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br J Cancer95(9):1212-1219.
107. Thiele, E. H., R. N.Arison, and G. E.Boxer. 1964a. Oncolysis by Clostridia. Iii. Effects of clostridia and chemotherapeutic agents on rodent tumors. Cancer Res24:222-233.
108. Thiele, E. H., R. N.Arison, and G. E.Boxer. 1964b. Oncolysis by clostridia. IV. Effect of nonpathogenic clostridial spores in normal and pathological tissues. Cancer Res24:234-238.
109. Toso, J. F., V. J.Gill, P.Hwu, F. M.Marincola, N. P.Restifo, D. J.Schwartzentruber, R. M.Sherryet al.2002. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol20(1):142-152.
110. van Pijkeren, J. P., D. Morrissey, I. R. Monk, M. Cronin, S. Rajendran, G. C.O’Sullivan, C. G.Gahan, and M.Tangney. 2010. A novel Listeria monocytogenes-based DNA delivery system for cancer gene therapy. Hum Gene Ther21(4):405-416.
111. Vassaux, G., J.Nitcheu, S.Jezzard, and N. R.Lemoine. 2006. Bacterial gene therapy strategies. J Pathol208(2):290-298.
112. Wallecha, A., P. C.Maciag, S.Rivera, Y.Paterson, and V.Shahabi. 2009. Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. Clin Vaccine Immunol16(1):96-103.
113. Weinrauch, Y. and A.Zychlinsky. 1999. The induction of apoptosis by bacterial pathogens. Annu Rev Microbiol53:155-187.
114. Xu, Y. F., L. P.Zhu, B.Hu, G. F.Fu, H. Y.Zhang, J. J.Wang, and G. X.Xu. 2007. A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy. Cancer Gene Ther14(2):151-157.
115. Yazawa, K., M.Fujimori, J.Amano, Y.Kano, and S.Taniguchi. 2000. Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors. Cancer Gene Ther7(2):269-274.
116. Yi, C., Y.Huang, Z. Y.Guo, and S. R.Wang. 2005. Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma. Acta Pharmacol Sin26(5):629-634.
117. Yu, Y. A., S.Shabahang, T. M.Timiryasova, Q.Zhang, R.Beltz, I.Gentschev, W.Goebel, and A. A.Szalay. 2004. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol22(3):313-320.
118. Yu, Y. A., Q.Zhang, and A. A.Szalay. 2008. Establishment and characterization of conditions required for tumor colonization by intravenously delivered bacteria. Biotechnol Bioeng100(3):567-578.
119. Zhao, M., M. Yang, X. M. Li, P. Jiang, E. Baranov, S. Li, M. Xu, S.Penman, and R. M.Hoffman. 2005. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressingSalmonella typhimurium. Proc Natl Acad Sci USA102(3):755-760.
120. Zhong, Z., R. A.Kazmierczak, A.Dino, R.Khreis, A.Eisenstark, and H.Schatten. 2007. Salmonella-host cell interactions, changes in host cell architecture, and destruction of prostate tumor cells with genetically altered Salmonella. Microsc Microanal13(5):372-383.
121. Zhou, S.2005. Combination therapy with bacteria and angiogenesis inhibitors: Strangling cancer without mercy. Cancer Biol Ther4(8):846-847.
122. Zhu, L. P., Y.Yin, J.Xing, C.Li, L.Kou, B.Hu, Z. W.Wu, J. J.Wang, and G. X.Xu. 2009. Therapeutic efficacy of Bifidobacterium lon-gum-mediated human granulocyte colony-stimulating factor and/or endostatin combined with cyclophosphamide in mouse-transplanted tumors. Cancer Sci100(10):1986-1990.
123. Zou, W.2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer5(4):263-274.